logo

For the Inventor, By the Inventor

Vancouver, Canada

John Coleman

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignees: The University of British Columbia, University of Alberta. Active years: 2000-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Coleman. Retrieved from https://idiyas.com/inventor/john-coleman-yzbhjin3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 60.0


Average Co-Inventor Count = 7.1

ph-index = 5

Forward Citations = 102(Granted Patents)


Location History:

  • Halifax, CA (2009)
  • Vancouver, CA (2000 - 2010)

Company Filing History:

goldMedal5 out of 963 
 
The University of British Columbia
 patents
silverMedal2 out of 455 
 
University of Alberta
 patents
where one patent can have more than one assignee

Years Active: 2000-2010

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents
1. 7772397 - Biologically active peptides and compositions, their use (2010-08-10),
2. 7579323 - Hemiasterlin analogs (2009-08-25),
3. 7410951 - Biologically active peptides and compositions, their use (2008-08-12),
4. 6870028 - Biologically active peptides and compositions, their use (2005-03-22),
5. 6153590 - Biologically active peptides and compositions, their use (2000-11-28),

Title: The Innovative Contributions of John Coleman

Introduction

John Coleman is a notable inventor based in Vancouver, Canada, recognized for his significant contributions to the field of biochemistry. With a total of five patents to his name, Coleman has focused on developing innovative solutions that address critical health challenges, particularly in cancer treatment.

Latest Patents

Among his latest patents, Coleman has developed biologically active peptides and compositions that have shown promise in treating cancer. This invention relates to derivatives of hemiasterlin or Geodiamolide G, which possess anti-mitotic activities. These derivatives are represented by a general formula, wherein specific variables are defined in the patent specification. Additionally, he has created analogs of hemiasterlin, providing methods for their synthesis and use as cytotoxic and anti-mitotic agents.

Career Highlights

Throughout his career, John Coleman has worked with prestigious institutions, including the University of British Columbia and the University of Alberta. His research has not only advanced scientific understanding but has also paved the way for potential therapeutic applications in oncology.

Collaborations

Coleman has collaborated with esteemed colleagues such as Raymond John Andersen and Edward Piers. These partnerships have fostered a collaborative environment that enhances innovation and drives research forward.

Conclusion

John Coleman's work exemplifies the impact of innovative thinking in the field of biochemistry. His patents and collaborations highlight his commitment

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…